The increase in the Company’s FY 2024 financial performance compared to FY 2023 was primarily due to higher realized prices at Conda and higher sulfuric acid and dry product sales at Arraias, which ...

The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other ...

S&P 500 fourth quarter buybacks increased 7.4% as compared to the prior quarter, and were up 11% from the same period last ...